News

  • It is scary enough being treated for COVID-19 – why would a patient also consider being part of a research trial?

    Written by Dr Megan Rees, Chief Investigator, AustralaSian COVID-19 Clinical Trial, Respiratory and Sleep Physician, Royal Melbourne Hospital and ...
  • Convalescent plasma for COVID-19

    Convalescent plasma is a treatment arm in ASCOT. Participants are randomised (like the flip of a coin) to either receiving convalescent plasma or the usual best standard of care without convalescent plasma.
  • AustralaSian COVID-19 Trial (ASCOT) removes hydroxychloroquine and lopinavir/ritonavir arms of the trial

    Following reports that that hydroxychloroquine and lopinavir/ritonavir are not effective in reducing mortality from COVID-19, the AustralaSian COVID-19 Trial (ASCOT) Steering Committee has also made the decision to remove the hydroxychloroquine and lopinavir/ritonavir arms of the Trial.
  • Convalescent plasma treatment for COVID-19 introduced to ASCOT and REMAP-CAP trials

    Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat patients hospitalised with COVID-19. 

  • A COVID-19 Effect on Scientific Research

    The world, as we alive now know it, is in uncharted territory. COVID-19 has spread inexorably to every part of our planet. Governments, leaders, and health care policy professionals are engaging with health care providers, business and social experts to curb the march of fatality and disease. Economic and broader threats to communities are emerging daily. To face down this menace, all have responded with unparalleled speed.
  • Macquarie Group Foundation commits $1 million to the AustralaSian COVID-19 Trial

    The AustralaSian COVID-19 Trial (ASCOT) has received a significant funding commitment of $1 million from the Macquarie Group Foundation.
  • A Consumer Representative's experience working on a COVID-19 clinical trial

    Sue Anderson is the Consumer Representative on the AustralaSian COVID-19 Clinical Trial (ASCOT) Steering Committee. She writes here of her experience.
  • Getting a clinical trial site up and running

    Setting up a clinical trial can take many months, even years. However, over the last six months, research teams around the globe have been pushed to their limits to set up and conduct randomised clinical trials to the same gold standard that is expected during non-COVID-19 times, but in record time.
  • Statement from the Australasian COVID-19 Trial (ASCOT) Trial Steering Committee

    The ASCOT Trial Steering Committee met on June 9 2020 to discuss recent updates on hydroxychloroquine from external studies.
  • Responding to emerging data in the time of COVID-19

    Does hydroxychloroquine (HCQ) have a role in the treatment of COVID-19? Results of a large database published in The Lancet showing an increased mortality were cause for thought, discussion and convening of a host of meetings to consider how to progress a clinical trial with emerging evidence. 

  • AustralaSian COVID-19 Trial to proceed with hydroxychloroquine arm

    The governance committees for the AustralaSian COVID-19 Trial (ASCOT) have unanimously agreed that ASCOT should proceed with randomising patients to the hydroxychloroquine arms of the study.
  • Statement on the status of AustralaSian COVID-19 Trial (ASCOT)

    Following an observational study published in The Lancet on Friday, 22 May, the AustralaSian COVID-19 Trial (ASCOT) has paused patient recruitment pending deliberations by the governance and ethics committees overseeing the trial.